CollPlant partners with CELLINK to create a $2.8 billion regenerative breast implant market

Introduction: Over the past decade, regenerationmedicineand the field of tissue engineering has experienced unprecedented growth, 3DbiologyPrinting is starting to gain traction as a means of creating viable, transplantable organs.

On February 23, 2022, regenerative medicine specialist CollPlant announced a partnership with BICO
CELLINK
cooperation to improve its3D bioprintingbreast
Implants
output.
Both parties are currently developing
clinical
In previous trials, CollPlant’s bioprinted grafts can degrade over time and be replaced by bulk tissue, a treatment that proves to be more likely than traditional breast augmentation
Operation
safer. To scale up the production of these grafts, the company has now begun a partnership with CELLINK, which is expected to create a $2.8 billion market.

Cecilia Edebo, CEO of CELLINK, said: “We are delighted to be working with a partner who shares our values and passion for a healthy future. We look forward to making an impact in the breast implant industry and also looking forward to working with CollPlant Build a long-term partnership to advance in the broader field of tissue engineering and regenerative medicine.”

△CollPlant breast implants3D bioprintingwork process. Image via CollPlant.

Bioprinting based on rhCollagen

CollPlant’s core technology is the extraction of recombinant proteins from tobacco plants to replace animal or cadaver-derived collagen grafts. The recombinant protein, called “rhCollagen,” can be processed to resemble the type I collagen the body produces and can be implanted with a reduced risk of rejection, making it an ideal cornerstone of regenerative medicine.

Earlier, CollPlant worked with UnitedTherapeutics to 3D bioprint rhCollagen into transplantable lungs.Later expanded into the production of kidneys, as well as with3D SystemsCollaborate to create organizational and comprehensive 3D bioprinting solutions for third parties, mainly including the manufacture of bioprinters and bioinks.

Back in 2019, CollPlant also announced the development of its first regenerative breast implant. Composed of rhCollagen, patient fat cells and ECM components, these tissues are bioengineered to promote cell regeneration once injected into those seeking breast augmentation or reconstruction, and then gradually degrade, in the process, leaving no trace behind foreign pollutants.

Although not yet on the market, CollPlant said its breast implants could represent a “revolutionary alternative” to silicone implants or fat grafting procedures, both of which have risks of adverse events and volume loss limitations.

Scale up prosthesis production

To accelerate the production of regenerated breast tissue, CollPlant has now partnered with CELLINK, one of the early leaders in 3D bioprinting. As a result, CELLINK has embarked on its own expansion over the past two years or so, with support from BICO, as part of a broader strategy to seek synergies between biologics and advanced technologies, which it calls “bioconvergence.”

In this way, BICO acquired the precision dispensing company Scienion for 80 million euros and the famous 2PP for 50 million euros 3D printingExpert Nanoscribe, and took over MatTek for $68 million to speed up the development of its animal-free testing models.

After the parent company acquired these different technologies, CELLINK has managed to integrate some of them into its 3D bioprinting products. In addition to the extrusion-based BIO X, BIO X6, and INKREDIBLE+ systems, the company now sells the light-based Lumen X+ and Quantum X bios, the latter of which utilizes Nanoscribe 2PP to unlock ultra-precise cell deposition.

Using these high-throughput bioprintings and the technical expertise of the CELLINK team, CollPlant says it aims to overcome the last hurdle facing its implant development. The company has forged its second such partnership in less than a year after agreeing to work with 3D Systems in July last year to develop breast reconstruction therapy, adding that its latest deal will accelerate its implants. listing process.

Yehiel Tal, CEO of CollPlant, added: “We are very pleased to partner with CELLINK, a recognized leader in developing 3D bioprinting solutions for the life sciences industry. We believe in CELLINK’s expertise in high-throughput bioprinters and biomanufacturing will help us move towards successful commercialization of our technology and provide patients with a much-needed solution.”

△In addition to tissue transplantation,3D printingIt has also been used to create surgical guidelines for treating breast cancer patients. Image from ScientificReports magazine.

Advances in Breast Tissue Bioprinting Technology

Whether as a treatment for cancer survivors or as an alternative to breast augmentation surgery, 3D bioprinted tissue continues to make strides toward clinical viability. Just last month, French startup Healshape successfully raised $6.8 million to develop custom 3D bioprinted breast implants based on living patient cells.

Similarly, South Korean biotech company Plcoskin revealed in July 2021 that it would lead an international research project focused on creating new biodegradable breast tissue grafts.The company has started with Yonsei University andmedicalEquipment coating specialist LipoCoat collaborated, and the project received US$1.7 million from the European Commission.

Elsewhere, 3D printing is also commonly used to produce patient-specific surgical guidelines aimed at allowing female cancer survivors to preserve more breast tissue after mastectomy.For example, at the Asan Medical Center, scientists have successfully developed devices that enable
surgical
Doctors are able to save up to 1 centimeter of tissue from the tumor site and then use it to treat real, early-diagnosed patients.

(responsible editor: admin)

CollPlant partners with CELLINK to create a $2.8 billion regenerative breast implant market

0 Comments for “CollPlant partners with CELLINK to create a $2.8 billion regenerative breast implant market”

Leave a Reply Cancel reply